Table 2.

Efficacy of nirsevimab weight-band dose on different case definitions of medically attended LRTI to 150 days post-dose (intention-to-treat population)

	Placebo group (n=786)	Nirsevimab group (n=1564)	Relative risk reduction (95% CI)	p value
Medically attended RSV LRTI*	51 (6%)	19 (1%)	79·5% (65·9–87·7)	<0·0001
Hospital admission for medically attended RSV LRTI†	21 (3%)	9 (1%)	77·3% (50·3–89·7)	0·0002
Very severe RSV LRTI‡	18 (2%)	5 (<1%)	86·0% (62·5–94·8)	<0·0001
Medically attended LRTI of any cause‡§	149 (19%)	191 (12%)	35·4% (21·5–46·9)	<0·0001
Hospital admission for respiratory illness of any cause‡§	51 (6%)	57 (4%)	43·8% (18·8–61·1)	0·0022

Relative risk reduction (95% CI) and p values were estimated on the basis of Poisson regression with robust variance across all case definitions. LRTI=lower respiratory tract infection. RSV=respiratory syncytial virus.

^*The model included study code, treatment group, and stratification factors (age at randomisation and hemisphere) as covariates obtained from PROC MIANALYZE after missing data imputation.

^†The model included study and treatment group as covariates for pooled studies obtained from PROC MIANALYZE after missing data imputation.

^‡The model included treatment as a factor.

^§Included are all medically attended LRTIs according to the investigator's judgement, regardless of whether they met the clinical criteria for the definition of medically attended LRTI (appendix p 4).